0.45
—
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BioMark Diagnostics
Its shares trade on Canadian Securities Exchange under the ticker BUX.CN. It has been listed since 3 November 2014. In the fiscal year to 31 March 2026, it reported revenue of C$59,787 and a net loss of C$1.5m. At that date it held total assets of C$1.9m and shareholders' equity of C$331,063.
BioMark Diagnostics, Inc. engages in development and commercialization of cancer diagnostic solutions to detect, monitor, and assess treatment for cancer. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2014-11-03. The firm is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. The company has also developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 3 Nov 2014
- Website
- biomarkdiagnostics.com ↗
Leadership
Pay as last reported
- Mr. Rashid BuxPresident, Chief Executive Officer, Director, since 2025C$240,000
- Mr. Guoyu HuangChief Financial OfficerC$100,200
- Mr. Kai-ming ChengIndependent Director
- Dr. Bramhanand RamjiawanIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- BioMark Diagnostics Inc. develops liquid biopsy metabolic panels for early lung cancer detection in Canada.
- The company's molecular diagnostics platform uses metabolomics and machine learning for cancer prognosis.
- SSAT1 enzyme detection provides early carcinomas detection in pre-symptomatic stages.
Weaknesses
- BioMark Diagnostics Inc. has limited commercialization of cancer diagnostic solutions in the US market.
- The company's IPO in 2014 has not led to significant market expansion in Europe.
- BioMark Diagnostics Inc. lacks a strong presence in the Asian cancer diagnostics market.
Opportunities
- Expanding liquid biopsy metabolic panel use for early-stage lung cancer diagnosis in Canada.
- Leveraging Omics technology for new cancer diagnostics in the Health Care sector.
- Increasing adoption of SSAT1-based assays for cancer monitoring in the US market.
Threats
- Competition from established cancer diagnostics firms in the US market.
- Regulatory challenges for liquid biopsy assays in the European Union.
- Potential delays in clinical detection validation for SSAT1 enzyme assays.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.